Incyte Corporation (INCY) & Its Peers Critical Analysis
Incyte Corporation (NASDAQ: INCY) is one of 199 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Incyte Corporation to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
This is a summary of recent ratings and price targets for Incyte Corporation and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Incyte Corporation Competitors||484||2292||6259||120||2.66|
Incyte Corporation presently has a consensus target price of $144.90, suggesting a potential upside of 37.89%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 2.12%. Given Incyte Corporation’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Incyte Corporation is more favorable than its peers.
Earnings and Valuation
This table compares Incyte Corporation and its peers revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Incyte Corporation||$1.11 billion||$104.22 million||-131.35|
|Incyte Corporation Competitors||$220.75 million||-$39.68 million||3.32|
Incyte Corporation has higher revenue and earnings than its peers. Incyte Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
88.9% of Incyte Corporation shares are owned by institutional investors. Comparatively, 46.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 17.7% of Incyte Corporation shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Incyte Corporation has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Incyte Corporation’s peers have a beta of 1.62, indicating that their average share price is 62% more volatile than the S&P 500.
This table compares Incyte Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Incyte Corporation Competitors||-3,997.85%||-118.99%||-43.92%|
Incyte Corporation beats its peers on 10 of the 12 factors compared.
Incyte Corporation Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.